Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	75 mg of JZP-110	59
Overall Study	STARTED	150 mg JZP-110	59
Overall Study	STARTED	300 mg of JZP-110	59
Overall Study	STARTED	Placebo	59
Overall Study	COMPLETED	75 mg of JZP-110	49
Overall Study	COMPLETED	150 mg JZP-110	51
Overall Study	COMPLETED	300 mg of JZP-110	43
Overall Study	COMPLETED	Placebo	52
Overall Study	NOT COMPLETED	75 mg of JZP-110	10
Overall Study	NOT COMPLETED	150 mg JZP-110	8
Overall Study	NOT COMPLETED	300 mg of JZP-110	16
Overall Study	NOT COMPLETED	Placebo	7

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02348593/flow